<DOC>
	<DOCNO>NCT00111137</DOCNO>
	<brief_summary>The purpose study compare time hematopoietic response ( hemoglobin correction 12 g/dL great equal 2 g/dL increase baseline ) subject randomized receive darbepoetin alfa front load dose regimen receive recombinant human erythropoietin ( rHuEPO ) weekly dose regimen 12-week comparative treatment period .</brief_summary>
	<brief_title>Treatment Patients With Non-Myeloid Malignancies Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Subjects nonmyeloid malignancy plan receive cyclic chemotherapy 8 additional week Anemia ( hemoglobin [ hgb ] great equal 9.0g/dL less equal 11.0 g/dL ) relate cancer chemotherapy Karnofsky performance status great equal 50 % Serum bilirubin less equal 2.5 time upper limit normal range serum creatinine concentration less equal 2.0 mg/dL Acute myelogenous leukemia ( AML ) , chronic myelogenous leukemia ( CML ) , myelodysplastic syndrome Hematologic disorder previously associate anemia Active bleeding Iron deficiency Received erythropoietic therapy within 14 day prior randomization Unstable cardiac disease Known positive human immunodeficiency virus antibody hepatitis B surface antigen Known positive antibody response erythropoietic agent Currently enrol , yet complete least 30 day since end investigational device drug trial receive investigational agent ( ) approve indication Pregnant breast feeding Red blood cell ( RBC ) transfusion within 4 week screen Known hypersensitivity recombinant mammalianderived product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>darbepoetin alfa</keyword>
	<keyword>anemia</keyword>
	<keyword>Amgen</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>